Susquehanna Fundamental Investments LLC Buys Shares of 167,839 BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Susquehanna Fundamental Investments LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 167,839 shares of the company’s stock, valued at approximately $4,251,000. Susquehanna Fundamental Investments LLC owned about 0.09% of BridgeBio Pharma at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Janus Henderson Group PLC grew its holdings in BridgeBio Pharma by 189.7% during the 1st quarter. Janus Henderson Group PLC now owns 3,312,706 shares of the company’s stock worth $102,402,000 after acquiring an additional 2,169,143 shares during the last quarter. Vanguard Group Inc. increased its holdings in BridgeBio Pharma by 13.5% in the fourth quarter. Vanguard Group Inc. now owns 12,800,294 shares of the company’s stock valued at $516,748,000 after purchasing an additional 1,524,313 shares during the period. Capital Research Global Investors raised its position in BridgeBio Pharma by 101.1% during the 1st quarter. Capital Research Global Investors now owns 2,212,085 shares of the company’s stock worth $68,398,000 after purchasing an additional 1,111,975 shares during the last quarter. Altitude Crest Partners Inc. acquired a new position in BridgeBio Pharma during the 4th quarter worth about $30,462,000. Finally, Ensign Peak Advisors Inc grew its position in shares of BridgeBio Pharma by 44.5% in the 2nd quarter. Ensign Peak Advisors Inc now owns 1,646,202 shares of the company’s stock valued at $41,698,000 after buying an additional 506,845 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Brian C. Stephenson sold 4,155 shares of the stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $24.69, for a total transaction of $102,586.95. Following the completion of the transaction, the chief financial officer now directly owns 85,192 shares of the company’s stock, valued at approximately $2,103,390.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other BridgeBio Pharma news, CEO Neil Kumar sold 27,389 shares of the business’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $24.69, for a total value of $676,234.41. Following the sale, the chief executive officer now directly owns 4,897,443 shares in the company, valued at $120,917,867.67. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Brian C. Stephenson sold 4,155 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $24.69, for a total value of $102,586.95. Following the transaction, the chief financial officer now owns 85,192 shares of the company’s stock, valued at approximately $2,103,390.48. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,831,544 shares of company stock valued at $150,128,821. Company insiders own 24.66% of the company’s stock.

Analyst Upgrades and Downgrades

BBIO has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $70.00 price objective on shares of BridgeBio Pharma in a research note on Monday, September 16th. JPMorgan Chase & Co. reduced their price objective on shares of BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $43.00 price objective on shares of BridgeBio Pharma in a research report on Monday, September 16th. Evercore ISI dropped their target price on shares of BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Finally, Piper Sandler started coverage on BridgeBio Pharma in a report on Wednesday, September 4th. They set an “overweight” rating and a $46.00 price target for the company. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat.com, BridgeBio Pharma currently has an average rating of “Moderate Buy” and an average target price of $47.92.

BridgeBio Pharma Trading Up 1.9 %

BBIO opened at $24.94 on Monday. BridgeBio Pharma, Inc. has a 1-year low of $21.62 and a 1-year high of $44.32. The company has a market cap of $4.67 billion, a price-to-earnings ratio of -7.75 and a beta of 1.07. The company’s fifty day moving average price is $26.24 and its two-hundred day moving average price is $27.01.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.61. The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $3.96 million. The company’s revenue for the quarter was up 32.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.98) earnings per share. As a group, equities analysts forecast that BridgeBio Pharma, Inc. will post -2.54 earnings per share for the current fiscal year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.